Contact Us

News

Bora Pharmaceuticals Makes a Strategic Investment into Tanvex to Provide Global BioManufacturing Services.

Bora Pharmaceuticals Makes a Strategic Investment into Tanvex to Provide Global BioManufacturing Services.

Aug 27, 2024

  Taipei, Taiwan, August 27, 2024 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), today announced that its Board of Directors has approved a strategic investment into Tanvex Biopharma Co., Ltd. ("Tanvex", TWSE: 6541), whereby Bora Biologics, a wholly owned subsidiary of Bora and specialist large molecule CDMO, and Tanvex will combine their biomanufacturing facilities...

read more
Bora Completes Acquisition of US Sterile Fill/Finish Facility From Emergent

Bora Completes Acquisition of US Sterile Fill/Finish Facility From Emergent

Aug 20, 2024

TAIPEI, TAIWAN, August 20th 2024 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), a a global leader in pharmaceutical manufacturing, today announced that it has completed the acquisition from Emergent BioSolutions (“Emergent”, NYSE: EBS) of its sterile manufacturing facility in Baltimore-Camden, Maryland. The facility adds drug product fill/finish to Bora’s extensive...

read more
Bora Recognized with Dual Accolades at Asia Best Companies to Work for Awards 2024

Bora Recognized with Dual Accolades at Asia Best Companies to Work for Awards 2024

Jul 8, 2024

《HR Asia》, the leading HR magazine in Asia, recently announced the winners of the 2024 “The HR Asia Best Companies to Work for in Asia Awards.” Bora Pharmaceuticals stood out among nearly 370 participating companies, not only winning the prestigious HR Asia Best Companies to Work for in Asia Taiwan 2024 award for the second time but also receiving the HR Asia Most Caring Company Awards 2024, recognizing its commitment to the “People First” philosophy since its inception as one of the core competences of the Bora Group.

read more